XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	₩993.00	+1.22%	71,927
26-10-01	₩981.00	-0.41%	55,471
26-09-30	₩985.00	-1.40%	49,227
26-09-29	₩999.00	-1.28%	28,076

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-10-02			5-day change	1st Jan Change
993.00 ^KRW	+1.22%		-0.60%	-40.22%

25-08-14	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
24-11-21	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	17.17B 12.75M 11.33M 10.57M 9.64M 18.18M 1.23B 18.35M 128M 49.59M 627M 47.88M 46.84M 2.01B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	15.75B 11.7M 10.39M 9.7M 8.84M 16.68M 1.12B 16.83M 117M 45.49M 575M 43.92M 42.97M 1.84B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

25-08-14	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
24-11-21	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
24-07-16	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
24-07-08	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 day	+1.22%
1 week	-0.60%
Current month	+0.81%
1 month	-11.34%
3 months	-15.92%
6 months	-30.27%
Current year	-40.22%

Xcell Therapeutics Inc. Stock

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation: Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news: Xcell Therapeutics Inc.

News in other languages: Xcell Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	971	1,032
1 month	951	1,125
Current year	951	2,050
1 year	951	2,755
3 years	951	12,900
5 years	951	12,900
10 years	951	12,900

Manager	Title	Age	Since
U-Ri Lee CEO	Chief Executive Officer	54	2016-08-31
Hae-Min Jeong CTO	Chief Tech/Sci/R&D Officer	40	-
Soo-Rim Oh COO	Chief Operating Officer	65	-

Director	Title	Age	Since
Jong-Min Lee BRD	Director/Board Member	48	2026-03-26
Mahn-Soon Hwang BRD	Director/Board Member	56	-
U-Ri Lee BRD	Director/Board Member	54	2016-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	+1.22%	-0.60%	-61.73%	-	12.75M
ELI LILLY AND COMPANY	-0.61%	-3.43%	+36.07%	+117.61%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+35.72%	+64.82%	617B
ABBVIE INC.	+1.11%	-0.58%	+12.36%	+78.27%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.79%	+41.79%	356B
ROCHE HOLDING AG	-0.95%	-4.05%	+20.54%	+40.33%	333B
NOVARTIS AG	-1.46%	-2.89%	+10.57%	+26.54%	267B
ASTRAZENECA PLC	-1.35%	-5.43%	-6.17%	+8.82%	244B
AMGEN INC.	-1.04%	-2.79%	+35.30%	+54.42%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+28.44%	+97.54%	179B
Average	-0.56%	-3.24%	+17.29%	+58.90%	369.72B
Weighted average by Cap.	-0.60%	-3.33%	+29.07%	+71.15%

	2024	2025
Net sales	1.93B 1.44M 1.28M 1.19M 1.09M 2.05M 138M 2.07M 14.41M 5.59M 70.59M 5.39M 5.28M 227M	1.95B 1.45M 1.29M 1.2M 1.09M 2.06M 139M 2.08M 14.52M 5.63M 71.12M 5.43M 5.32M 228M
Net income	-9.54B -7.09M -6.3M -5.88M -5.36M -10.1M -681M -10.2M -71.11M -27.56M -348M -26.6M -26.03M -1.12B	-10.93B -8.11M -7.21M -6.73M -6.13M -11.57M -780M -11.67M -81.43M -31.55M -399M -30.46M -29.8M -1.28B
Net Debt	-3.1B -2.3M -2.05M -1.91M -1.74M -3.28M -221M -3.31M -23.1M -8.95M -113M -8.64M -8.46M -363M	-1.42B -1.05M -936K -874K -797K -1.5M -101M -1.52M -10.58M -4.1M -51.8M -3.96M -3.87M -166M